 Patients presenting with heart failure with signs of left ventricular LV systolic dysfunction who are eligible to receive ACE-Inhibitors in addition to standard therapy e.g., digitalis and diuretics can be enrolled into this trial. Patients who previously presented with LV systolic dysfunction and who have already been treated with ACE-Inhibitors, and currently still have an indication for the use of an ACE-Inhibitor can be switched to an equivalent starting dose of enalapril ODMT. 